heat shock protein family B (small) member 2Genealiases: HSP27 · Hs.78846 · LOH11CR1K · MKBP
Q-omics provides the consensus-scored HSPB2 profile across patient tissues and cancer cell-line models. HSPB2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HSPB2 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, HSPB2 RNA expression shows 14,493 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, BLCA, and TGCT as cancer lineages where HSPB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPB2 survival associations across molecular data types. HSPB2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPB2 RNA expression–survival associations across cancer types. High HSPB2 expression shows unfavorable associations in STAD, HNSC, OV, SCLC and LGG, but favorable associations in KIRP. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for HSPB2 RNA expression.
This table summarizes HSPB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HSPB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPB2 shows lower tumor expression in BLCA, LUAD, COAD and LUSC and higher tumor expression in KIRC and KIRP. The BLCA box plot shows higher HSPB2 RNA expression in normal versus tumor tissue (log2 FC = −2.687, t-test p < 0.001).
This table shows molecular features associated with HSPB2 in patient tissues and cancer cell lines. In patient samples, HSPB2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HSPB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
